Sign in

RADX on Nasdaq

Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd is a pharmaceutical preparations company, listed on Nasdaq (RADX).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Marker Therapeutics, Inc., Camp4 Therapeutics Corp or Kala Pharmaceuticals (United States), or pick any stock.

  • TickerRADX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersC31
  • Incorporated inAustralia2
  • Business addressLevel 3, 62 Lygon Street, Carlton Vic, 30532
  • Filer categoryNon-accelerated filer, Emerging growth company2

See how the biggest companies compare on our leaderboards

Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

1.1%Gross margin4
-1050.6%Operating margin4
-1055.3%Net margin4
-89.4%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue11¢$3.6M
  • Research and development88¢$27.5M
  • Interest0¢$65.3K
  • Income tax0¢$103.3K

Out of $3.6M in revenue.4 The company lost money this year.

Financial statements

Gross profit4$39.3K in 2025−87% since 2023
0$100.0K$200.0K$300.0K2023: $292.4K$292.4K20232024: $299.2K$299.2K2024+2%2025: $39.3K$39.3K2025−87%
Operating income4-$38.2M in 2025+11% since 2023
-$60.0M-$40.0M-$20.0M02023: -$34.5M-$34.5M20232024: -$47.2M-$47.2M2024+37%2025: -$38.2M-$38.2M2025−19%
Net income4-$38.3M in 2025+11% since 2023
-$60.0M-$40.0M-$20.0M02023: -$34.6M-$34.6M20232024: -$47.9M-$47.9M2024+39%2025: -$38.3M-$38.3M2025−20%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2026-06-302025-06-302024-06-30
Revenue from contracts with customers2.8M AUD3.6M AUD299.2K AUD
Cost of sales-$2.5M-$3.6M
Gross Profit$263.4K$39.3K$299.2K
Other income$10.7M$10.3M$1.3M
Other losses-$868.2K-$351.6K-$1.2M
General and administrative expenses-$16.2M-$14.6M-$13.0M
Research and development expenses-$50.0M-$27.5M-$23.1M
Share-based payments expenses-$2.4M-$1.9M-$2.6M
Gain/(loss) on movement in contingent consideration$1.7M-$4.1M-$8.9M
Operating loss-$56.8M-$38.2M-$47.2M
Finance expenses-$112.4K-$65.3K-$642.9K
Loss before income tax-$56.9M-$38.2M-$47.9M
Income tax expense-$54.4K-$103.3K-$96.4K
Loss for the year-$57.0M-$38.3M-$47.9M
Exchange differences on translation of foreign operations$621.4K$464.0K$203.0K
Owners of Radiopharm Theranostics Limited-$54.5M-$36.2M-$45.8M
Non-controlling interests-$1.8M-$1.6M-$2.0M
Total comprehensive loss for the year-$56.3M-$37.9M-$47.7M
Basic loss per share (in Dollars per share)-$1.79-$1.76-$12.41
Diluted loss per share (in Dollars per share)-$1.79-$1.76-$12.41

Compare Radiopharm Theranostics Ltd with another company

Corporate structure

Radiopharm Theranostics Ltd sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Radiopharm Theranostics Ltd

  • Radiopharm Theranostics Ltd C3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Radiopharm Theranostics Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$53.5K4 Jun 30, 2025$60.8K4 Jun 30, 2024−12.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$29.1M4 Jun 30, 2025$18.6M4 Jun 30, 2024+56.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$46.6M4 Jun 30, 2025$49.1M4 Jun 30, 2024−5.1%

Leadership

Who has led Radiopharm Theranostics Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Riccardo Canevari2026–now

Chief financial officer

  1. Aaron James Laurita2026–now
Board members and other officers (6)

Timeline

  1. Mar 31, 2026New chief executive Riccardo Canevari becomes CEO6

Filings

157 filings to the SEC since October 2021: 3 annual reports, 8 insider forms, 10 large holders, 136 other. The latest 20:

  1. Oct 14, 2026SCHEDULE 13G EDGAR
  2. Oct 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 30, 202620-F ANNUAL REPORT EDGAR
  5. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 23, 2026EFFECT EDGAR
  7. Sep 23, 2026424B3 PROSPECTUS EDGAR
  8. Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Sep 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Sep 14, 2026F-3 REGISTRATION STATEMENT EDGAR
  11. Sep 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Sep 4, 2026SCHEDULE 13G EDGAR
  14. Sep 4, 2026SCHEDULE 13D EDGAR
  15. Aug 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Aug 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Aug 26, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Aug 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Aug 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Aug 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 157 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Stonepine Capital Management, LLC51,000,000$670.5K0.5%No change
Hsbc Holdings PLC62,188$253.7K0.0%+816
Regal Partners Ltd40,138$168.2K0.0%No change
PNC Financial Services Group, Inc.20,000$83.8K0.0%+4,000
UBS Group AG1,507$6.3K0.0%−1,493
Integrated Wealth Concepts LLC1,310$5.5K0.0%New
Rhumbline Advisers195$8170.0%+74

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Radiopharm Theranostics Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRadiopharm Theranostics Ltd1
  • CIK0001949257
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company3
  • Incorporated inAustralia3
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressLevel 3, 62 Lygon Street, Carlton Vic, 3053, Australia1
  • Phone61 3 9824 52541
  • Shares outstanding3,544,216,160 shares as of Jun 30, 20263
  • AuditorGRANT THORNTON AUDIT PTY LTD, Melbourne, Australia PCAOB ID 2233; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceDec 16, 20221
  • Filings157 in all: 6-K (88), CORRESP (10), 3 (8), 20FR12B/A (7), SCHEDULE 13G (7), UPLOAD (7), EFFECT (5), 424B3 (3)1
    All 22 form types

    424B5 (3), F-3 (3), 20-F (2), F-6/A (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 20-F/A (1), 20FR12B (1), CERT (1), DRS (1), F-1 (1), F-6 (1), SCHEDULE 13D (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (20-F) Sep 30, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary Shares, as represented by American Depositary SharesRADXNasdaq

From the cover page of the 20-F filed Sep 30, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16